BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 26689913)

  • 1. Patterns and functional implications of rare germline variants across 12 cancer types.
    Lu C; Xie M; Wendl MC; Wang J; McLellan MD; Leiserson MD; Huang KL; Wyczalkowski MA; Jayasinghe R; Banerjee T; Ning J; Tripathi P; Zhang Q; Niu B; Ye K; Schmidt HK; Fulton RS; McMichael JF; Batra P; Kandoth C; Bharadwaj M; Koboldt DC; Miller CA; Kanchi KL; Eldred JM; Larson DE; Welch JS; You M; Ozenberger BA; Govindan R; Walter MJ; Ellis MJ; Mardis ER; Graubert TA; Dipersio JF; Ley TJ; Wilson RK; Goodfellow PJ; Raphael BJ; Chen F; Johnson KJ; Parvin JD; Ding L
    Nat Commun; 2015 Dec; 6():10086. PubMed ID: 26689913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated analysis of germline and somatic variants in ovarian cancer.
    Kanchi KL; Johnson KJ; Lu C; McLellan MD; Leiserson MD; Wendl MC; Zhang Q; Koboldt DC; Xie M; Kandoth C; McMichael JF; Wyczalkowski MA; Larson DE; Schmidt HK; Miller CA; Fulton RS; Spellman PT; Mardis ER; Druley TE; Graubert TA; Goodfellow PJ; Raphael BJ; Wilson RK; Ding L
    Nat Commun; 2014; 5():3156. PubMed ID: 24448499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
    Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
    Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.
    Foretová L; Navrátilová M; Svoboda M; Vašíčková P; Sťahlová EH; Házová J; Kleiblová P; Kleibl Z; Macháčková E; Palácová M; Petráková K
    Klin Onkol; 2019; 32(Supplementum2):6-13. PubMed ID: 31409076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy.
    Ellingson MS; Hart SN; Kalari KR; Suman V; Schahl KA; Dockter TJ; Felten SJ; Sinnwell JP; Thompson KJ; Tang X; Vedell PT; Barman P; Sicotte H; Eckel-Passow JE; Northfelt DW; Gray RJ; McLaughlin SA; Moreno-Aspitia A; Ingle JN; Moyer AM; Visscher DW; Jones K; Conners A; McDonough M; Wieben ED; Wang L; Weinshilboum R; Boughey JC; Goetz MP
    Breast Cancer Res Treat; 2015 Sep; 153(2):435-43. PubMed ID: 26296701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
    Rasnic R; Brandes N; Zuk O; Linial M
    BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.
    Schubert S; van Luttikhuizen JL; Auber B; Schmidt G; Hofmann W; Penkert J; Davenport CF; Hille-Betz U; Wendeburg L; Bublitz J; Tauscher M; Hackmann K; Schröck E; Scholz C; Wallaschek H; Schlegelberger B; Illig T; Steinemann D
    Int J Cancer; 2019 Jun; 144(11):2683-2694. PubMed ID: 30426508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
    PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia.
    Cock-Rada AM; Ossa CA; Garcia HI; Gomez LR
    Fam Cancer; 2018 Jan; 17(1):23-30. PubMed ID: 28528518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy.
    Silvestri V; Rizzolo P; Falchetti M; Zanna I; Masala G; Bianchi S; Palli D; Ottini L
    Breast Cancer Res Treat; 2011 Apr; 126(2):539-43. PubMed ID: 21165771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of PALB2-associated breast cancers.
    Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
    J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
    Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
    JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline RAD51C mutations in ovarian cancer susceptibility.
    Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
    Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
    Girard E; Eon-Marchais S; Olaso R; Renault AL; Damiola F; Dondon MG; Barjhoux L; Goidin D; Meyer V; Le Gal D; Beauvallet J; Mebirouk N; Lonjou C; Coignard J; Marcou M; Cavaciuti E; Baulard C; Bihoreau MT; Cohen-Haguenauer O; Leroux D; Penet C; Fert-Ferrer S; Colas C; Frebourg T; Eisinger F; Adenis C; Fajac A; Gladieff L; Tinat J; Floquet A; Chiesa J; Giraud S; Mortemousque I; Soubrier F; Audebert-Bellanger S; Limacher JM; Lasset C; Lejeune-Dumoulin S; Dreyfus H; Bignon YJ; Longy M; Pujol P; Venat-Bouvet L; Bonadona V; Berthet P; Luporsi E; Maugard CM; Noguès C; Delnatte C; Fricker JP; Gesta P; Faivre L; Lortholary A; Buecher B; Caron O; Gauthier-Villars M; Coupier I; Servant N; Boland A; Mazoyer S; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
    Int J Cancer; 2019 Apr; 144(8):1962-1974. PubMed ID: 30303537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare genetic variants and the risk of cancer.
    Bodmer W; Tomlinson I
    Curr Opin Genet Dev; 2010 Jun; 20(3):262-7. PubMed ID: 20554195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
    Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
    BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
    Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inherited Mutations in Women With Ovarian Carcinoma.
    Norquist BM; Harrell MI; Brady MF; Walsh T; Lee MK; Gulsuner S; Bernards SS; Casadei S; Yi Q; Burger RA; Chan JK; Davidson SA; Mannel RS; DiSilvestro PA; Lankes HA; Ramirez NC; King MC; Swisher EM; Birrer MJ
    JAMA Oncol; 2016 Apr; 2(4):482-90. PubMed ID: 26720728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic findings in breast, fallopian tube, and ovary specimens in non-BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C, BARD1, BRIP1, PALB2, MUTYH, or CHEK2.
    Schoolmeester JK; Moyer AM; Goodenberger ML; Keeney GL; Carter JM; Bakkum-Gamez JN
    Hum Pathol; 2017 Dec; 70():14-26. PubMed ID: 28709830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.